Showing results (11-20 of 23) with videos related to
Sort By:
Pageof 3
Cancer Immunology Research|February 19, 2022
CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous RetrovirusesYu Chen, Qiaomei Cai, Chaohu Pan, et al.Cancer Medicine|October 22, 2022
Integrated tumor genomic and immune microenvironment analysis identifies predictive biomarkers associated with the efficacy of neoadjuvant therapy for triple-negative breast cancerYanhui Zhu, Hongfei Zhang, Chaohu Pan, et al.Frontiers in Immunology|May 9, 2022
Predicting Durable Responses to Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Using a Multi-Feature ModelLei Wang, Hongbing Zhang, Chaohu Pan, et al.Cell Reports|January 26, 2022
Histone deacetylase 3 contributes to the antiviral innate immunity of macrophages by interacting with FOXK1 to regulate STAT1/2 transcriptionLiping Yang, Shengchuan Chen, Qun Zhao, et al.Frontiers in Genetics|December 19, 2022
Integrated investigation of the prognostic role of HLA LOH in advanced lung cancer patients with immunotherapyXiaotao Zhang, Hongzhen Tang, Haitao Luo, et al.Cell & Bioscience|June 30, 2021
ADP-ribosyltransferase PARP11 suppresses Zika virus in synergy with PARP12Lili Li, Yueyue Shi, Sirui Li, et al.Journal of Proteome Research|August 17, 2023
Proteomic Profiling and Tumor Microenvironment Characterization Reveal Molecular and Immunological Hallmarks of Left-Sided and Right-Sided Colon Cancer TumorigenesisZhu Hong, Tao Wang, Wei Wang, et al.Cellular & Molecular Immunology|November 16, 2021
Homeoprotein SIX1 compromises antitumor immunity through TGF-β-mediated regulation of collagensWancheng Liu, Meiling Gao, Lili Li, et al.Cell & Bioscience|February 17, 2024
Interferon-stimulated gene PVRL4 broadly suppresses viral entry by inhibiting viral-cellular membrane fusionQiaomei Cai, Nina Sun, Yurui Zhang, et al.Ebiomedicine|March 15, 2023
Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trialGuoqing Zhang, Jing Yuan, Chaohu Pan, et al.Pageof 3